Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: Preliminary results

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Piccardo, Arnoldo ^a   Paparo, Francesco ^a   Picazzo, Riccardo ^a   Naseri, Mehrdad ^a   Ricci, Paolo ^a   Marziano, Andrea ^a   Bacigalupo, Lorenzo ^a   Biscaldi, Ennio ^a   Rollandi, Gian Andrea ^a   Grillo Ruggieri, Filippo ^a   Farsad, Mohsen ^b  

^a GALLIERA HOSPITAL   (Italy)

^b Nuclear Medicine Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE F18; IASOCHOLINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUOROMETHYLCHOLINE;

AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PELVIS LYMPH NODE; PELVIS LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE CANCER; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; STANDARD UPTAKE VALUE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; PROCEDURES; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIOGRAPHY; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROTON THERAPY;

EID: 84901349139     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/103718     Document Type: Article

References (18)

1. Chism D. B., Hanlon A. L., Horwitz E. M., Feigenberg S. J., Pollack A., A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2004 59 2 380 385 2-s2.0-2442510047 10.1016/j.ijrobp.2003.10.059 (Pubitemid 38622589)
2. Roach M. III, Hanks G., Thames H. Jr., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics 2006 65 4 965 974 10.1016/j.ijrobp.2006.04.029
3. Slovin S. F., Wilton A. S., Heller G., Scher H. I., Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clinical Cancer Research 2005 11 24 8669 8673 2-s2.0-29344458751 10.1158/1078-0432.CCR-05-1668 (Pubitemid 43005915)
4. Older R. A., Lippert M. C., Gay S. B., Omary R. A., Hillman B. J., Computed tomography appearance of the prostatic fossa following radical prostatectomy. Academic Radiology 1995 2 6 472 474 2-s2.0-0029311522 10.1016/S1076-6332(05)80401-5
5. Leventis A. K., Shariat S. F., Slawin K. M., Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001 219 2 432 439 2-s2.0-0035064474 (Pubitemid 32336357)
6. 18F- Fluoride PET/CT. The Journal of Nuclear Medicine 2006 47 2 287 297 2-s2.0-33746187320 (Pubitemid 46780894)
7. Wu L. M., Xu J. R., Gu H. Y., Hua J., Zhu J., Chen J., Zhang W., Hu J., Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clinical Oncology 2013 25 4 252 264 10.1016/j.clon.2012.11.010
8. 18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging 2006 33 12 1387 1398 2-s2.0-33845357517 10.1007/s00259-006-0150-2 (Pubitemid 44885404)
9. 18F]-choline PET/CT for staging and restaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 2 253 263 2-s2.0-38349088040 10.1007/s00259-007-0552-9
10. 11C- Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. European Journal of Nuclear Medicine and Molecular Imaging 2014 41 5 878 886 10.1007/s00259-013-2655-9
11. 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Investigative Radiology 2013 48 5 256 262 10.1097/RLI.0b013e318282c654
12. 18F]choline PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 2014 41 1 79 88 10.1007/s00259-013-2560-2
13. 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Molecular Imaging and Biology 2011 13 2 352 361 2-s2.0-79955937462 10.1007/s11307-010-0337-6
14. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Schmid H.-P., van der Kwast T., Wiegel T., Zattoni F., EAU guidelines on prostate cancer-part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 2011 59 1 61 71 2-s2.0-78649362120 10.1016/j.eururo.2010.10.039
15. Barentsz J. O., Richenberg J., Clements R., Choyke P., Verma S., Villeirs G., Rouviere O., Logager V., Fütterer J. J., ESUR prostate MR guidelines 2012. European Radiology 2012 22 4 746 757 2-s2.0-84856596608 10.1007/s00330-011-2377-y
16. 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 9 1356 1364 10.1007/s00259-013-2433-8
17. Park H., Wood D., Hussain H., Meyer C. R., Shah R. B., Johnson T. D., Chenevert T., Piert M., Introducing parametric fusion PET/MRI of primary prostate cancer. The Journal of Nuclear Medicine 2012 53 4 546 551 2-s2.0-84859381916 10.2967/jnumed.111.091421
18. 18F fluoride PET-CT: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 10 1766 1774 2-s2.0-52449111808 10.1007/s00259-008-0788-z